# Bioequivalence Study of Perampanel Tablets 12 mg

> **NCT06450223** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 30 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Perampanel 12 MG
- **DRUG:** Fycompa 12 mg film-coated tablets

## Key facts

- **NCT ID:** NCT06450223
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-14
- **Primary completion:** 2023-09-20
- **Final completion:** 2023-12-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06450223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06450223, "Bioequivalence Study of Perampanel Tablets 12 mg". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06450223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*